南京北恒生物科技有限公司 Nanjing North Hang Seng Material Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Bioheng Biotech Announces Publication of Impressive Results with CD7-targeted allogeneic CAR-T cell therapy for Relapsed or Refractory T Cell Malignancies 2022-09-26 21:00
China CDE Approved First Universal CAR-T IND ! 2022-03-17 21:32
CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA 2022-01-28 22:00
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL. 2021-06-20 21:00
Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies 2021-03-24 22:01
Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r/r B-ALL Treatment at 2020 ASH Meeting 2020-11-10 22:30
1